MDBH

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

3 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. More Detailed Information 2025 Annual Shareholder Letter HERE. Form 10-K HERE. Key Assets and Strategic Developments eXoZymes (NASDAQ:EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately $30 million based on March 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization

Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, "The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine." The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy. Over the past eighteen months, more than $19 billion in deal value has been committed across the amylin space, with major pharmaceutical companies, including Novo Nordisk, Eli Lilly, Roche, Pfizer, and AbbVie, actively building positions. The report highlights

10-K - MDB Capital Holdings, LLC (0001934642) (Filer)

Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced a new addition to its IP Legal Insights section on the company website, a platform dedicated to sharing expert legal perspectives on intellectual property strategy, emerging technology, and innovation-driven industries. The IP Legal Insights section serves as a resource for founders, executives, and investors seeking to better understand how intellectual property decisions impact innovation, competitive positioning, and long-term business value. Through this platform, PatentVest's legal and technical experts provide analysis on key patent law developments, practical prosecution strategies, and emerging trends shapin

Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest, a leading provider of IP Strategy and Legal services, today announced a strategic engagement with Life Seal Vascular and disclosed that it has accepted equity in the company as partial consideration for its services. The arrangement reflects PatentVest's conviction in Life Seal Vascular's underlying technology and its potential to reshape the vascular device market. Life Seal Vascular joins a portfolio of life sciences and medtech clients leveraging PatentVest's proprietary IP platform to map competitive IP landscapes, that identify patenting opportunities and risks, and inform strategic decision-making across R&D, licensing, and

Addison, TX, March 23, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing the results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and may be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for

Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) -- PatentVest announced the completion of a strategic intellectual property engagement with Porosome Therapeutics, Inc., a biotechnology company developing a first-in-class therapeutic platform designed to restore cellular secretion mechanisms. The collaboration focused on evaluating and strengthening Porosome Therapeutics' intellectual property portfolio to support future partnerships, commercialization efforts, and capital strategy initiatives. PatentVest conducted a comprehensive IP portfolio audit, global patent landscape analyses, competitive benchmarking, and strategic partner assessment. Porosome Therapeutics is advancing Porosome Recons

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, "The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron." As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range. In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program's patent portfolio. The report

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Addison, Texas, Feb. 02, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading "Big Idea" companies, today announced the appointment of Jeb Terry, Sr to its Board of Directors and extended its sincere gratitude to Susanne Meline as she concluded her dedicated and influential board service. Both transitions are effective as of February 1, 2026. Jeb Terry brings to the MDB board more than two decades of investment in microcap medical and biotechnology companies, where he has consistently identified and capitalized on high-potential opportunities in this dynamic and innovation-driven sector. He founded and s

8-K - MDB Capital Holdings, LLC (0001934642) (Filer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

Dallas, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced the release of a new PatentVest Pulse report, The Patent Battlefield: How IP Portfolios Reveal the True Winners in the $1.8 Trillion Space Economy, a first-of-its-kind analysis using patent data to reveal who is positioned to win as the space sector goes mainstream. With Elon Musk's SpaceX rumored to pursue a historic IPO, the report examines whether today's leading space companies have the intellectual property foundations required to sustain long-term value under public-market scrutiny. Based on an analysis of 1,450+ launch-related patent families, the report reveals: Why Elon Musk's SpaceX patent portfolio point

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

4 - MDB Capital Holdings, LLC (0001934642) (Issuer)

PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic, South-East, and Texas (K4-MST), together with MDB Capital Holdings, LLC (NASDAQ:MDBH), today announced the successful completion of the Southeast Investor Conference in Atlanta and the Mid-Atlantic Investor Summit in Philadelphia, two investor-first events designed to reset how accredited angels and venture partners approach early-stage capital, syndication, and exits. Across both events, more than 150 accredited investors, family offices, and venture ecosystem leaders came together to dissect current market realities, debunk myths that keep investor groups siloed, and develop practical pathways to higher-quality